Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Denali Therapeutics (DNLI) initiated with a Buy at Janney Montgomery Scott. 2. PhaseBio (PHAS) initiated with a Buy at Stifel and Citi as well as an Outperform at Cowen. 3. Osmotica Pharmaceuticals (OSMT) initiated with a Buy at Jefferies as well as an Outperform at Wells Fargo and RBC Capital. 4. SI-Bone (SIBN) initiated with an Outperform at JMP Securities, an Overweight at Morgan Stanley, as well as a Buy at Canaccord and BofA/Merrill. 5. Studio City (MSC) initiated with an Underweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

Osmotica Pharmaceuticals initiated with a Buy at Jefferies. Jefferies analyst David Steinberg started Osmotica Pharmaceuticals with a Buy rating and $21 price target. Utilizing its osmotic drug delivery technology platform, the company is transforming itself from a predominantly generic drug maker with 40 products to one that is comprised of clinically differentiated, longer duration pharmaceuticals, Steinberg tells investors in a research note.

Osmotica Pharmaceuticals initiated with an Outperform at Wells Fargo. Wells Fargo analyst David Maris started coverage of Osmotica Pharmaceuticals with an Outperform rating and $17.50 price target. The analyst estimates that over the next five years and driven by new product launches, Osmotica sales will nearly double, and its proportion of sales coming from higher margin branded products will likely increase from approximately 22% in 2018 to 70% by 2023.

Osmotica Pharmaceuticals initiated with an Outperform at RBC Capital. RBC Capital analyst Randall Stanicky initiated Osmotica Pharmaceuticals with an Outperform rating and a price target of $17. The analyst is positive on the track record of the company's management along with its valuation, stating that his discounted cash flow analysis suggests that the value of its "current largely high barrier generic base business roughly covers equity value". Stanicky further contends that Osmotica Pharmaceuticals valuation leaves out a "compelling optionality on two sizable brand opportunities", with phase 3 data on both expected in the first half of next year.